Abbonarsi

Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study - 27/09/17

Doi : 10.1016/j.ahj.2017.03.012 
Rajesh Vedanthan, MD, MPH a, , Jemima H. Kamano, MBChB, MMed b, c, Hana Lee, PhD d, Benjamin Andama c, Gerald S. Bloomfield, MD, MPH e, Allison K. DeLong, MS d, David Edelman, MD e, Eric A. Finkelstein, PhD, MHA, MA e, Joseph W. Hogan, ScD, MS d, Carol R. Horowitz, MD, MPH a, Simon Manyara, BPharm c, Diana Menya, MBChB, Msc f, Violet Naanyu, PhD b, Sonak D. Pastakia, PharmD, MPH c, g, Thomas W. Valente, PhD h, Cleophas C. Wanyonyi c, Valentin Fuster, MD, PhD a
a Icahn School of Medicine at Mount Sinai, New York, NY, USA 
b Moi University College of Health Sciences, School of Medicine, Eldoret, Kenya 
c Academic Model Providing Access to Healthcare, Eldoret, Kenya 
d Brown University, Providence, RI, USA 
e Duke University, Durham, NC, USA 
f Moi University College of Health Sciences, School of Public Health, Eldoret, Kenya 
g Purdue University, West Lafayette, IN, USA 
h University of Southern California, Los Angeles, CA, USA 

Reprint requests: Rajesh Vedanthan MD, MPH, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.Icahn School of Medicine at Mount SinaiOne Gustave L. Levy PlaceBox 1030

Abstract

Background

Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with >80% of CVD deaths occurring in low and middle income countries (LMICs). Diabetes mellitus and pre-diabetes are risk factors for CVD, and CVD is the major cause of morbidity and mortality among individuals with DM. There is a critical period now during which reducing CVD risk among individuals with diabetes and pre-diabetes may have a major impact. Cost-effective, culturally appropriate, and context-specific approaches are required. Two promising strategies to improve health outcomes are group medical visits and microfinance.

Methods/Design

This study tests whether group medical visits integrated into microfinance groups are effective and cost-effective in reducing CVD risk among individuals with diabetes or at increased risk for diabetes in western Kenya. An initial phase of qualitative inquiry will assess contextual factors, facilitators, and barriers that may impact integration of group medical visits and microfinance for CVD risk reduction. Subsequently, we will conduct a four-arm cluster randomized trial comparing: (1) usual clinical care, (2) usual clinical care plus microfinance groups only, (3) group medical visits only, and (4) group medical visits integrated into microfinance groups. The primary outcome measure will be 1-year change in systolic blood pressure, and a key secondary outcome measure is 1-year change in overall CVD risk as measured by the QRISK2 score. We will conduct mediation analysis to evaluate the influence of changes in social network characteristics on intervention outcomes, as well as moderation analysis to evaluate the influence of baseline social network characteristics on effectiveness of the interventions. Cost-effectiveness analysis will be conducted in terms of cost per unit change in systolic blood pressure, percent change in CVD risk score, and per disability-adjusted life year saved.

Discussion

This study will provide evidence regarding effectiveness and cost-effectiveness of interventions to reduce CVD risk. We aim to produce generalizable methods and results that can provide a model for adoption in low-resource settings worldwide.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Paul W. Armstrong, MD served as guest editor for this article.
 RCT# NCT02501746
 Research Funder: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (award number 1R01HL125487-01A1), under the Global Alliance for Chronic Diseases program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


© 2017  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 188

P. 175-185 - giugno 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure—Trial design of the REDUCE FMR study
  • Steven L. Goldberg, Ian Meredith, Thomas Marwick, Brian A. Haluska, Janusz Lipiecki, Tomasz Siminiak, Nawzer Mehta, David M. Kaye, Horst Sievert, for the REDUCE FMR Investigators
| Articolo seguente Articolo seguente
  • Feasibility of exercise stress echocardiography and myocardial response in patients with repaired congenital heart disease
  • Babar S. Hasan, Fatima I. Lunze, Najveen Alvi, Keri M. Shafer, Jonathan Rhodes

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.